346 related articles for article (PubMed ID: 16174135)
1. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
2. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia.
Grootendorst P; Stewart D
Health Econ; 2006 Jul; 15(7):735-42. PubMed ID: 16498702
[TBL] [Abstract][Full Text] [Related]
3. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.
Grootendorst PV; Dolovich LR; O'Brien BJ; Holbrook AM; Levy AR
CMAJ; 2001 Oct; 165(8):1011-9. PubMed ID: 11699696
[TBL] [Abstract][Full Text] [Related]
4. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.
Marshall JK; Grootendorst PV; O'Brien BJ; Dolovich LR; Holbrook AM; Levy AR
CMAJ; 2002 Jun; 166(13):1655-62. PubMed ID: 12126319
[TBL] [Abstract][Full Text] [Related]
5. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients.
Smalley WE; Griffin MR; Fought RL; Sullivan L; Ray WA
N Engl J Med; 1995 Jun; 332(24):1612-7. PubMed ID: 7753141
[TBL] [Abstract][Full Text] [Related]
6. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
Morgan SG; Agnew JD; Barer ML
Health Policy; 2004 Jun; 68(3):299-307. PubMed ID: 15113641
[TBL] [Abstract][Full Text] [Related]
7. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program.
Anderson GM; Kerluke KJ; Pulcins IR; Hertzman C; Barer ML
Inquiry; 1993; 30(2):199-207. PubMed ID: 8314608
[TBL] [Abstract][Full Text] [Related]
8. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.
Schneeweiss S; Dormuth C; Grootendorst P; Soumerai SB; Maclure M
Med Care; 2004 Jul; 42(7):653-60. PubMed ID: 15213490
[TBL] [Abstract][Full Text] [Related]
9. Public drug expenditure in the Republic of Ireland.
Barry M; Usher C; Tilson L
Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
[TBL] [Abstract][Full Text] [Related]
10. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
[TBL] [Abstract][Full Text] [Related]
11. Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan.
Morgan SG
Health Serv Res; 2002 Oct; 37(5):1243-66. PubMed ID: 12479495
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
[TBL] [Abstract][Full Text] [Related]
13. The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.
Li X; Guh D; Lacaille D; Esdaile J; Anis AH
Health Policy; 2007 Aug; 82(3):340-7. PubMed ID: 17134787
[TBL] [Abstract][Full Text] [Related]
14. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
Fischer MA; Avorn J
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
[TBL] [Abstract][Full Text] [Related]
15. Reference-based pricing in British Columbia: implications for cardiologists--an analysis.
Boulet AP; Tessier G
Can J Cardiol; 1997 Jan; 13(1):46-51. PubMed ID: 9039064
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
McManus P; Birkett DJ; Dudley J; Stevens A
Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
18. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta.
Hogan DB; Campbell NR; Crutcher R; Jennett P; MacLeod N
CMAJ; 1994 Aug; 151(3):315-22. PubMed ID: 8039085
[TBL] [Abstract][Full Text] [Related]
19. Generic drug utilisation on the General Medical Services (GMS) scheme in 2001.
Tilson L; McGowan B; Ryan M; Barry M
Ir Med J; 2003 Jun; 96(6):176-9. PubMed ID: 12926759
[TBL] [Abstract][Full Text] [Related]
20. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
Barozzi N; Tett SE
Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
